STOCK TITAN
  1. Home
  2. Sec-filings
  3. EVMN
  4. [Form 4] Evommune, Inc. Insider Trading Activity

Evommune (EVMN) CEO sells 7,438 shares in pre-set 10b5-1 stock plan

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Evommune, Inc. director and President & CEO Luis C. Pena reported an open-market sale of 7,438 shares of common stock on June 22, 2026 at a weighted average price of $22.71 per share. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 2, 2026, indicating they were scheduled in advance. Following this sale, Pena directly holds 630,458 shares of Evommune common stock, so the sale represents only a small portion of his overall stake.

Positive

  • None.

Negative

  • None.
Insider Pena Luis C.
Role President & CEO
Sold 7,438 shs ($169K)
Type Security Shares Price Value
Sale Common Stock 7,438 $22.71 $169K
Holdings After Transaction: Common Stock — 630,458 shares (Direct, null)
Footnotes (1)
  1. The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2026. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $22.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
Shares sold 7,438 shares Open-market sale on June 22, 2026
Weighted average sale price $22.71 per share Common stock sale by CEO
Post-transaction holdings 630,458 shares Shares directly held after sale
Price range of sales $22.50–$22.99 per share Multiple transactions within this range
Trading plan adoption date March 2, 2026 Rule 10b5-1 plan governing sales
Rule 10b5-1 trading plan regulatory
"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Pena Luis C.
(Last)(First)(Middle)
C/O EVOMMUNE, INC.
1891 PAGE MILL ROAD
(Street)
PALO ALTO CALIFORNIA 94304
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Evommune, Inc. [ EVMN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President & CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/22/2026S(1)7,438D$22.71(2)630,458D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2026.
2. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $22.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
Remarks:
/s/ Gregory S. Moss, Attorney-in-Fact06/24/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Evommune (EVMN) CEO Luis C. Pena report in this Form 4 filing?

Luis C. Pena reported selling 7,438 Evommune common shares. The open-market sale occurred on June 22, 2026 at a weighted average price of $22.71 per share, and was executed under a pre-arranged Rule 10b5-1 trading plan.

How many Evommune (EVMN) shares did the CEO sell and at what price?

The CEO sold 7,438 shares at a weighted average of $22.71. The filing notes the sale occurred in multiple trades at prices ranging from $22.50 to $22.99 per share, with the average price reported in the main transaction line.

How many Evommune (EVMN) shares does Luis C. Pena hold after this transaction?

After the sale, Luis C. Pena directly holds 630,458 shares. This remaining position, disclosed in the Form 4, shows that the 7,438 shares sold represent only a small fraction of his overall Evommune common stock holdings.

Was the Evommune (EVMN) CEO’s share sale under a Rule 10b5-1 trading plan?

Yes, the sale was executed under a Rule 10b5-1 trading plan. A footnote explains the transactions were made pursuant to a trading plan adopted by Luis C. Pena on March 2, 2026, indicating they were pre-scheduled rather than discretionary.

What price range did Evommune (EVMN) shares trade at in the CEO’s Form 4 sale?

The reported sales occurred between $22.50 and $22.99 per share. The Form 4 footnote states that the weighted average price was $22.71, with multiple individual transactions executed across that specified price range.

Is the Evommune (EVMN) CEO’s Form 4 transaction a buy or sell action?

The Form 4 reports a sell transaction by the CEO. The filing classifies it as an open-market sale of common stock, with 7,438 shares sold and no corresponding purchases or derivative exercises reported in this specific filing.